Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy
Lists
Only you see this
Abstract
Re-challenge with gefitinib is effective and could be a choice for third-line patients after the first-line EGFR-TKI treatment and second-line chemotherapy, especially for the T790M-negative patients.
BibTeX
@inproceedings{song2019efficacy,
author = {Yong Jung Song and Yi‐Long Wu and Lejie Cao and Jianhua Chen and Zhiyong Ma and Jiuwei Cui and Jie Wang and Hongbing Liu and Jingyan Ding and Min Hu},
title = {{Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy}},
booktitle = {American},
year = {2019},
doi = {10.1097/coc.0000000000000538},
}Loading related content...